MA39770A - Protéines agonistes du récepteur trail monocaténaires - Google Patents

Protéines agonistes du récepteur trail monocaténaires

Info

Publication number
MA39770A
MA39770A MA039770A MA39770A MA39770A MA 39770 A MA39770 A MA 39770A MA 039770 A MA039770 A MA 039770A MA 39770 A MA39770 A MA 39770A MA 39770 A MA39770 A MA 39770A
Authority
MA
Morocco
Prior art keywords
receptor agonist
agonist proteins
trail
chain trail
trail receptor
Prior art date
Application number
MA039770A
Other languages
English (en)
French (fr)
Inventor
Fritz G Buchanan
Christian Gieffers
Oliver Hill
Susan E Lappe
Darren C Phillips
Meinolf Thiemann
Original Assignee
Abbvie Inc
Apogenix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Apogenix Ag filed Critical Abbvie Inc
Publication of MA39770A publication Critical patent/MA39770A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
MA039770A 2014-04-23 2015-04-23 Protéines agonistes du récepteur trail monocaténaires MA39770A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
MA39770A true MA39770A (fr) 2015-10-29

Family

ID=53055121

Family Applications (2)

Application Number Title Priority Date Filing Date
MA045069A MA45069A (fr) 2014-04-23 2015-04-23 Protéines agonistes du récepteur trail monocaténaires
MA039770A MA39770A (fr) 2014-04-23 2015-04-23 Protéines agonistes du récepteur trail monocaténaires

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA045069A MA45069A (fr) 2014-04-23 2015-04-23 Protéines agonistes du récepteur trail monocaténaires

Country Status (38)

Country Link
US (5) US9908927B2 (enExample)
EP (2) EP3134430B1 (enExample)
JP (2) JP6523331B2 (enExample)
KR (2) KR102079919B1 (enExample)
CN (2) CN106459221B (enExample)
AR (1) AR100168A1 (enExample)
AU (3) AU2015249649B2 (enExample)
BR (1) BR112016024515B1 (enExample)
CA (2) CA3184067A1 (enExample)
CL (1) CL2016002683A1 (enExample)
CR (1) CR20160516A (enExample)
CY (1) CY1120281T1 (enExample)
DK (1) DK3134430T3 (enExample)
DO (1) DOP2016000284A (enExample)
EC (1) ECSP16089579A (enExample)
ES (1) ES2672368T3 (enExample)
HR (1) HRP20180950T1 (enExample)
HU (1) HUE038914T2 (enExample)
IL (2) IL248244B (enExample)
LT (1) LT3134430T (enExample)
MA (2) MA45069A (enExample)
MX (2) MX2016013858A (enExample)
MY (1) MY181986A (enExample)
NO (1) NO2776305T3 (enExample)
PE (1) PE20170299A1 (enExample)
PH (2) PH12020500377A1 (enExample)
PL (1) PL3134430T3 (enExample)
PT (1) PT3134430T (enExample)
RS (1) RS57153B1 (enExample)
RU (1) RU2699285C2 (enExample)
SG (3) SG11201608767XA (enExample)
SI (1) SI3134430T1 (enExample)
SM (1) SMT201800286T1 (enExample)
TR (1) TR201806912T4 (enExample)
TW (2) TWI747178B (enExample)
UA (1) UA118286C2 (enExample)
UY (1) UY36095A (enExample)
WO (1) WO2015164588A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023646A2 (pt) 2015-05-04 2018-07-17 Apogenix Ag proteínas agonistas de receptor de cd40 de cadeia simples
CA3002602C (en) 2015-10-23 2021-11-02 Apogenix Ag Single-chain cd27-receptor agonist proteins
CA3002587A1 (en) 2015-10-23 2017-04-27 Apogenix Ag Single-chain light receptor agonist proteins
CN108473549A (zh) * 2015-10-23 2018-08-31 阿珀吉科吉尼科斯股份公司 单链gitr受体激动剂蛋白
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
JP7091248B2 (ja) 2016-03-01 2022-06-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 低減されたｌ－グルタミナーゼ活性および増強された安定性を有するｌ－アスパラギナーゼ変異体および融合タンパク質
KR20180127407A (ko) * 2016-03-16 2018-11-28 메리맥 파마슈티컬즈, 인크. 암 요법용 조작된 trail
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
AU2017283487A1 (en) * 2016-06-13 2018-11-22 Merrimack Pharmaceuticals, Inc. Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
WO2019032952A1 (en) * 2017-08-11 2019-02-14 The Board Of Trustees Of The University Of Illinois TRUNCATED VARIANTS OF INDIA PIG ASPARAGINASE AND METHODS OF USE
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
WO2019178438A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
CN115836084A (zh) 2020-05-15 2023-03-21 阿珀吉尼科斯股份公司 多特异性免疫调节剂
CA3217894A1 (en) 2021-05-28 2022-12-01 Gernot Stuhler Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025984A1 (es) 1999-10-07 2002-12-26 Maxygen Aps Polipeptidos oligomericos de cadena simple
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
ATE406384T1 (de) 2000-12-07 2008-09-15 Lilly Co Eli Glp-1 fusion proteine
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003234274A1 (en) 2002-04-26 2003-11-10 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US8388962B2 (en) 2005-04-15 2013-03-05 Rappaport Family Institute For Research In The Medical Sciences Molecules and methods of using same for treating MCP-1/CCR2 associated diseases
WO2006116260A2 (en) 2005-04-26 2006-11-02 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
ES2560871T3 (es) 2007-07-10 2016-02-23 Apogenix Gmbh Proteínas de fusión de colectina de la superfamilia de TNF
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5674155B2 (ja) * 2008-07-21 2015-02-25 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ Ｔｎｆｓｆ一本鎖分子
CA2737280A1 (en) * 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
EP2379585A2 (en) * 2008-10-10 2011-10-26 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
EP2829550B1 (en) 2009-01-09 2016-11-16 Apogenix AG Fusion proteins forming trimers
JP2012515556A (ja) * 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
TW201130511A (en) 2009-12-22 2011-09-16 Novartis Ag Soluble proteins for use as therapeutics
AU2011240620A1 (en) 2010-04-13 2012-10-18 Medimmune, Llc Fibronectin type III domain-based multimeric scaffolds
US9717803B2 (en) * 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
CA2878992C (en) 2012-07-18 2020-09-22 Apogenix Gmbh Composition comprising a mixture of cd95-fc isoforms

Also Published As

Publication number Publication date
AR100168A1 (es) 2016-09-14
RS57153B1 (sr) 2018-07-31
JP2017513503A (ja) 2017-06-01
PL3134430T3 (pl) 2018-08-31
RU2699285C2 (ru) 2019-09-04
RU2016145608A3 (enExample) 2018-12-26
CA2946402C (en) 2023-02-28
CA2946402A1 (en) 2015-10-29
IL272612A (en) 2020-03-31
US20240174731A1 (en) 2024-05-30
EP3366699A1 (en) 2018-08-29
US20250145688A1 (en) 2025-05-08
EP3134430A1 (en) 2017-03-01
IL248244B (en) 2020-03-31
RU2016145608A (ru) 2018-05-28
JP2019162114A (ja) 2019-09-26
SG10202111785VA (en) 2021-12-30
CN106459221B (zh) 2020-09-01
TWI747178B (zh) 2021-11-21
PE20170299A1 (es) 2017-05-06
PH12016502079A1 (en) 2016-12-19
MX2016013858A (es) 2017-08-02
ES2672368T3 (es) 2018-06-14
LT3134430T (lt) 2018-05-10
SMT201800286T1 (it) 2018-07-17
KR20190135546A (ko) 2019-12-06
JP6523331B2 (ja) 2019-05-29
MX2019013587A (es) 2020-01-13
CA3184067A1 (en) 2015-10-29
MY181986A (en) 2021-01-18
BR112016024515B1 (pt) 2020-03-31
PH12020500377A1 (en) 2022-11-14
US20180222962A1 (en) 2018-08-09
SG10201806465TA (en) 2018-08-30
AU2015249649A1 (en) 2016-11-10
AU2020202247A1 (en) 2020-04-23
TW202024123A (zh) 2020-07-01
UY36095A (es) 2015-10-30
BR112016024515A2 (pt) 2017-10-10
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
AU2015249649B2 (en) 2018-10-04
TR201806912T4 (tr) 2018-06-21
KR20170012257A (ko) 2017-02-02
US20150337027A1 (en) 2015-11-26
HUE038914T2 (hu) 2018-12-28
EP3134430B1 (en) 2018-03-21
TWI683825B (zh) 2020-02-01
NO2776305T3 (enExample) 2018-01-27
NZ725476A (en) 2023-09-29
CR20160516A (es) 2017-05-10
KR102079919B1 (ko) 2020-02-24
SG11201608767XA (en) 2016-11-29
US9908927B2 (en) 2018-03-06
JP6714751B2 (ja) 2020-06-24
UA118286C2 (uk) 2018-12-26
SI3134430T1 (en) 2018-05-31
CL2016002683A1 (es) 2017-07-07
TW201620928A (zh) 2016-06-16
ECSP16089579A (es) 2018-05-31
HRP20180950T1 (hr) 2018-08-10
CY1120281T1 (el) 2019-07-10
WO2015164588A1 (en) 2015-10-29
PH12016502079B1 (en) 2016-12-19
AU2018271369A1 (en) 2018-12-20
DOP2016000284A (es) 2017-02-15
DK3134430T3 (en) 2018-05-22
PT3134430T (pt) 2018-04-20
CN106459221A (zh) 2017-02-22
US20210040178A1 (en) 2021-02-11
MA45069A (fr) 2019-04-03
IL248244A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
MX2019013587A (es) Proteinas agonistas del receptor del ligando que induce la apoptosis relacionada con el factor de necrosis de tumor de cadena individual.
IL278014A (en) Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
MX2017014140A (es) Proteinas agonistas receptoras cd40 de cadena simple.
IL251194A0 (en) Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
PL3559034T3 (pl) Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
EP3679071A4 (en) PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
PH12016501644B1 (en) Binding proteins and methods of use thereof
SG11201610812WA (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2018001787A (es) Proteinas de fusion del ligando de la proteina relacionada con el receptor de factor de necrosis tumoral inducido por glucorticoides (gitrl) y usos de las mismas.
AR102879A1 (es) Métodos para el tratamiento de tumores cerebrales
UA117045C2 (uk) Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
IL254242A0 (en) Dual signaling fusion proteins and methods of using them to treat diseases
MX2017011991A (es) Terapia virica con una combinacion de anticuerpos.
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
EP3778644A3 (en) Fgfr-tacc fusion proteins and methods thereof
EP3227681A4 (en) Anti-acetaminophen antibodies and acetaminophen protein adducts
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1
NZ761611A (en) Single-chain trail-receptor agonist proteins
EA202092450A2 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей